BET inhibitor nanotherapy halts kidney damage and reduces chronic kidney disease progression after ischemia-reperfusion injury

BET inhibitor nanotherapy halts kidney damage and reduces chronic kidney disease progression after ischemia-reperfusion injury

Targeting epigenetic mechanisms has emerged as a potential therapeutic approach for the treatment of kidney diseases. Specifically, inhibiting the bromodomain and extra-terminal (BET) domain proteins using the small molecule inhibitor JQ1 has shown promise in preclinical models of acute kidney injur...

Full description

Bibliographic Details
Main Authors: Maria Laura Saiz, Laura Lozano-Chamizo, Aida Bernardo Florez, Marzia Marciello, Paula Diaz-Bulnes, Viviana Corte-Iglesias, Cristian Ruiz Bernet, Raul R. Rodrigues-Diez, Cristina Martin-Martin, Mar Rodriguez-Santamaria, Ivan Fernandez-Vega, Ramon M. Rodriguez, Carmen Diaz-Corte, Beatriz Suarez-Alvarez, Marco Filice, Carlos Lopez-Larrea
Format: Article
Language:English
Published: Elsevier 2024-05-01
Series:Biomedicine & Pharmacotherapy
Subjects:
AKI
ischemia reperfusion injury
BRD4
JQ1
nanobiotechnology
kidney drug delivery
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332224003767

Internet

http://www.sciencedirect.com/science/article/pii/S0753332224003767

Similar Items